search
Back to results

Impact of Oral Application of Gastrografin on the Meconium Evacuation in Very Low Birth Weight Infants

Primary Purpose

Meconium Ileus, Very Low Birth Weight Infant

Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Gastrografin
Sterile water
Sponsored by
Nadja Haiden,MD
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Meconium Ileus focused on measuring VLBW infant, Meconium, Enteral nutrition, Meconium passage

Eligibility Criteria

undefined - 24 Hours (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • premature infants with a birthweight < 1500g and a gestational age < 32 weeks

Exclusion Criteria:

  • major congenital disorders
  • chromosomal aberrations
  • systemic metabolic disease and
  • pre-existing gastrointestinal abnormalities (i.e. Morbus Hirschsprung)
  • pre-existing conditions of severe hypotension

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Placebo Comparator

    Arm Label

    Gastrografin

    Sterile water

    Arm Description

    infants receive 3ml/kg Gastrografin + 6ml/kg sterile water

    infants receive 9ml/kg sterile water

    Outcomes

    Primary Outcome Measures

    Time to Complete Meconium Evacuation in Days
    Time to complete meconium evacuation in days of life until the complete meconium evacuation from birth up to 40 days of life

    Secondary Outcome Measures

    Feeding Tolerance- Full Enteral Feedings
    full enteral feeding is defined in days of life from birth until an an infant tolerates an enteral feeding volume of 140ml/kg

    Full Information

    First Posted
    January 10, 2012
    Last Updated
    June 17, 2014
    Sponsor
    Nadja Haiden,MD
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01515696
    Brief Title
    Impact of Oral Application of Gastrografin on the Meconium Evacuation in Very Low Birth Weight Infants
    Official Title
    Impact of Oral Application of Gastrografin on the Meconium Evacuation in Very Low Birth Weight Infants- a Phase 4 Study
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2014
    Overall Recruitment Status
    Completed
    Study Start Date
    October 2007 (undefined)
    Primary Completion Date
    October 2010 (Actual)
    Study Completion Date
    February 2011 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor-Investigator
    Name of the Sponsor
    Nadja Haiden,MD

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Gastrografin is a radiopaque contrast agent for the gastrointestinal tract (GIT) which can be applied orally or rectally. In neonatal intensive care, Gastrografin is used to detect otherwise radiologically invisible perforations or an insufficient GIT anastomosis after surgery. Furthermore it is used for the treatment of meconium ileus. Gastrografin has a strong osmotic effect and leads to water influx into the intestine lumen. Thereby the peristaltic movement is accelerated and the premature infant excretes stool during the hours following application. Therefore Gastrografin might be effective to mobilize meconium from small bowel and deep parts of the colon. The investigators hypothesized that enteral application of Gastrografin accelerates meconium evacuation in premature infants, and thereby enhances feeding tolerance in this population.
    Detailed Description
    In premature infants the establishment of proper gastrointestinal function is challenging and often associated with delayed meconium passage. Meconium evacuation depends on gestational age and birthweight: the more immature an infant is, the later meconium passage starts and the longer meconium passage lasts. The mean duration of meconium evacuation in premature infants with a gestational age below 30 weeks is 8 days, while mature infants excrete their meconium in 2 days. The obstruction of deep intestinal segments by tenacious, sticky meconium frequently leads to gastric residuals, a distended abdomen and delayed food passage. The time lag to full enteral feedings is extended, the probability to acquire infections due to intravenous access for parenteral nutrition increases and the hospital stay of the infant is prolonged. However, the relation between meconium passage and feeding tolerance remains controversial. While one study showed that there is little concordance between first meconium passage and feeding tolerance, an other one showed that rapid and complete excretion of meconium is crucial for oral feeding tolerance and has a positive effect on it. Recently, the investigators performed a prospective randomized trial to determine, whether repeated prophylactic applications of small volume glycerin enemas accelerate passage of meconium in very low birth weight (VLBW) infants. Disappointingly, application of enemas did not accelerate meconium evacuation. A possible reason for the ineffectiveness of glycerin enemas is that the volume used was too small to mobilize tenacious meconium sufficiently from the colon and small bowel. Gastrografin is a radiopaque contrast agent for the gastrointestinal tract (GIT) which can be applied orally or rectally. In neonatal intensive care, Gastrografin is used to detect otherwise radiologically invisible perforations or an insufficient GIT anastomosis after surgery. Furthermore it is used for the treatment of meconium ileus. Gastrografin has a strong osmotic effect and leads to water influx into the intestine lumen. Thereby the peristaltic movement is accelerated and the premature infant excretes stool during the hours following application. Therefore Gastrografin might be more effective to mobilize meconium from small bowel and deep parts of the colon. The investigators hypothesized, that enteral application of Gastrografin accelerates meconium evacuation in premature infants, and thereby enhances feeding tolerance in this population. The objective of the present study is to determine whether the enteral application of the osmotic contrast agent Gastrografin® accelerates complete meconium excretion and improves feeding tolerance in very low birth weight infants.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Meconium Ileus, Very Low Birth Weight Infant
    Keywords
    VLBW infant, Meconium, Enteral nutrition, Meconium passage

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigator
    Allocation
    Randomized
    Enrollment
    96 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Gastrografin
    Arm Type
    Active Comparator
    Arm Description
    infants receive 3ml/kg Gastrografin + 6ml/kg sterile water
    Arm Title
    Sterile water
    Arm Type
    Placebo Comparator
    Arm Description
    infants receive 9ml/kg sterile water
    Intervention Type
    Drug
    Intervention Name(s)
    Gastrografin
    Other Intervention Name(s)
    Diatrizoate Meglumine, Diatrizoate Sodium, NDA-011245
    Intervention Description
    Patients will receive 3ml Gastrografin + 6ml sterile water/kg as a single dose via a nasogastric tube during the first 24 hours of life.
    Intervention Type
    Drug
    Intervention Name(s)
    Sterile water
    Other Intervention Name(s)
    Sterile water (ANDA) #077393
    Intervention Description
    Patients will receive 9ml/kg sterile water as a single dose via a nasogastric tube during the first 24 hours of life.
    Primary Outcome Measure Information:
    Title
    Time to Complete Meconium Evacuation in Days
    Description
    Time to complete meconium evacuation in days of life until the complete meconium evacuation from birth up to 40 days of life
    Time Frame
    days of life until until the complete meconium evacuation from birth up to 40 days of life
    Secondary Outcome Measure Information:
    Title
    Feeding Tolerance- Full Enteral Feedings
    Description
    full enteral feeding is defined in days of life from birth until an an infant tolerates an enteral feeding volume of 140ml/kg
    Time Frame
    days of life from birth until an infant tolerates en enteral feeding volume of 140 ml/kg

    10. Eligibility

    Sex
    All
    Maximum Age & Unit of Time
    24 Hours
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: premature infants with a birthweight < 1500g and a gestational age < 32 weeks Exclusion Criteria: major congenital disorders chromosomal aberrations systemic metabolic disease and pre-existing gastrointestinal abnormalities (i.e. Morbus Hirschsprung) pre-existing conditions of severe hypotension
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Nadja Haiden, MD
    Organizational Affiliation
    Medical university of Vienna, Department of Pediatrics
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Impact of Oral Application of Gastrografin on the Meconium Evacuation in Very Low Birth Weight Infants

    We'll reach out to this number within 24 hrs